Neuphoria Therapeutics Inc. (NEUP): Revenue
$1.17M
Year ended 2026-06-30
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $1.17M | -92.5% | 2026-09-18, From 2025-07-01 |
| 2025-06-30 | $15.65M | n/a | 2026-09-18, From 2024-07-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $1.17M | -92.5% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $1.20M | -49.9% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $1.14M | -34.6% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $1.27M | +161.1% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $1.27M | -5.5% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $1.03M | n/m |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $1.36M | +66.1% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $1.01M | +65.5% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $1.38M | -0.3% |
Compare NEUP, LGVN, SXTC, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗